Kadmon Holdings (NYSE: KDMN) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Kadmon Holdings to related companies based on the strength of its earnings, dividends, institutional ownership, analyst recommendations, valuation, profitability and risk.
This is a summary of recent recommendations for Kadmon Holdings and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kadmon Holdings Competitors||128||793||1733||59||2.64|
Kadmon Holdings presently has a consensus price target of $5.50, suggesting a potential upside of 53.20%. As a group, “Biopharmaceuticals” companies have a potential upside of 15.82%. Given Kadmon Holdings’ higher possible upside, equities analysts clearly believe Kadmon Holdings is more favorable than its competitors.
This table compares Kadmon Holdings and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kadmon Holdings Competitors||-13,597.63%||-103.31%||-25.61%|
Earnings and Valuation
This table compares Kadmon Holdings and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Kadmon Holdings||$26.06 million||-$208.75 million||-2.05|
|Kadmon Holdings Competitors||$563.95 million||$96.15 million||54.26|
Kadmon Holdings’ competitors have higher revenue and earnings than Kadmon Holdings. Kadmon Holdings is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
27.5% of Kadmon Holdings shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 8.4% of Kadmon Holdings shares are owned by insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Kadmon Holdings has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500. Comparatively, Kadmon Holdings’ competitors have a beta of 1.22, suggesting that their average stock price is 22% more volatile than the S&P 500.
Kadmon Holdings competitors beat Kadmon Holdings on 8 of the 12 factors compared.
About Kadmon Holdings
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.